HOME >> BIOLOGY >> NEWS
Researchers discover gene causing deadly infantile form of genetic kidney disease

Identification of gene PKHD1 brings hope of cure to sufferers of autosomal recessive polycystic kidney disease

Kansas City, Mo. (February 6, 2002) Researchers at the Mayo Clinic have identified and fully characterized the gene that causes autosomal recessive polycystic kidney disease (ARPKD), raising hopes of a treatment and eventual cure for infants born with ARPKD. The Polycystic Kidney Disease (PKD) Foundation provided grants that led to the promising discovery of the PKHD1 gene, an effort aided by earlier work done at the Human Genome Project. The March 2002 issue of Nature Genetics will feature this breakthrough.

ARPKD is one of a group of polycystic kidney diseases that together make up the worlds most common life-threatening genetic disease, affecting 600,000 children and adults in the United States and 12.5 million people worldwide. In the U.S., more people have PKD than the combined number of those who have cystic fibrosis, muscular dystrophy, Downs syndrome, hemophilia, sickle cell anemia and Huntingtons disease. The disease affects people equally irrespective of age, race, gender, ethnicity, geographic location or socioeconomic status.

ARPKD, often referred to as infantile PKD, is a particularly lethal form of PKD resulting in the development of multiple fluid-filled cysts in the kidney and fibrosis in the liver. The disease is often associated with poor lung development and infant death. There is currently no treatment or cure for ARPKD, but the discovery of the ARPKD gene now provides researchers with a genetic road map for a functional understanding of how PKD progresses, and paves the way for gene testing, more conclusive diagnosis, and treatments to retard development of the disease.

Identifying the causative gene is a major step forward as the basic defect and progression of the disease can now be studied, said Peter C. Harris, Ph.D., of the Mayo Clinic and the lead researcher in the study. The
'"/>

Contact: Jim Guarnera
jguarner@hillandknowlton.com
212-885-0303
Hill and Knowlton
6-Feb-2002


Page: 1 2

Related biology news :

1. Researchers determine genetic cause of Timothy syndrome
2. Researchers find color sensitive atomic switch in bacteria
3. Researchers identify protein promoting vascular tumor growth
4. Researchers devise potent new tools to curb ivory poaching
5. Researchers create nanotubes that change colors, form nanocarpet and kill bacteria
6. Researchers ID chlorophyll-regulating gene
7. Researchers develop fast track way to discover how cells are regulated
8. Researchers identify distinctive signature for metastatic prostate cancer
9. Researchers report new gene test for isolated cleft lip and palate
10. Researchers discover why mutant gene causes colon cancer
11. Researchers identify the genomes controlling elements

Post Your Comments:
(Date:2/25/2015)... ROCK, Ark. , Feb. 25, 2015 /PRNewswire/ ... software and billing in the Health and Fitness ... as well as to MYiCLUBonline.  The latest upgrade ... and the inclusion of cardless check-in via Identity ... for the first time through interactive displays at ...
(Date:2/23/2015)... Conn. , Feb. 23, 2015 NXT-ID, ... or the "Company"), a biometric authentication company focused on ... has filed provisional patent 62114357 for DISTRIBUTED ... this patent, NXT-ID introduces a new groundbreaking payment method. ... the payment account may only be accessed if both ...
(Date:2/12/2015)... Minn. , Feb. 12, 2015   ... company specializing in clinical study management systems, has ... Program , further distinguishing iMedNet ... Clinical Research Organizations (CROs) and healthcare consultants.  Building ... support, prospective customer referrals and numerous co-marketing opportunities), ...
Breaking Biology News(10 mins):ABC Financial Unveils New Software Enhancements 2ABC Financial Unveils New Software Enhancements 3NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2
(Date:3/6/2015)... Die SARAH-Studie ... Assistance Publique - Hôpitaux de ... französische, gemeinschaftliche, randomisierte Kontrollstudie für die mehr ... werden Patienten mit fortgeschrittenem hepatozellulärem Karzinom (HCC), ... behandelt wurden. Die Ergebnisse werden für Ende ...
(Date:3/5/2015)... , March 5, 2015   HX360 ... semi-finalists in the HX360 Innovation Challenge competition. ... will compete to be chosen as one of four ... of senior health system executives and venture capitalists during ... Innovation Challenge takes place at the 2015 HIMSS Annual ...
(Date:3/5/2015)... Altamonte Springs, FL (PRWEB) March 05, 2015 ... Jamie Damm for the position of Vice President of ... support managed care relationships for one of the nation’s ... Seattle, brings more than 15 years of specialty pharmacy ... Previously Damm worked with Raptor Pharmaceuticals, Vertex Pharmaceuticals, and ...
(Date:3/5/2015)... TORONTO , March 5, 2015 /PRNewswire/ - Aptose ... developing new therapeutics and molecular diagnostics that target the ... G. Rice , Ph.D., Chairman, President and Chief Executive ... Conference on Tuesday, March 10 th at 9:30 ... Laguna Niguel, CA. Dr. Rice will provide ...
Breaking Biology Technology:Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 2Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 3Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 4Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 5Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 6HX360 Announces Sixteen Innovation Challenge Semi-finalists Competing To Deliver Solutions That Improve The Patient Experience 2HX360 Announces Sixteen Innovation Challenge Semi-finalists Competing To Deliver Solutions That Improve The Patient Experience 3HX360 Announces Sixteen Innovation Challenge Semi-finalists Competing To Deliver Solutions That Improve The Patient Experience 4BioPlus Specialty Pharmacy Announces Hiring of New Vice President of Managed Care: Jamie Damm 2Aptose Biosciences to Present at the 27th Annual ROTH Conference 2Aptose Biosciences to Present at the 27th Annual ROTH Conference 3
Cached News: